View More Recent Stories

May 26, 2021 05:13PM Legend Biotech (LEGN) Announces FDA Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
May 26, 2021 05:11PM U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
May 12, 2021 12:11PM Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings
Apr 30, 2021 06:49AM Legend Biotech (LEGN) Announces Submission of European MAA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel for Treatment of R/R Multiple Myeloma
Apr 30, 2021 06:38AM Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multipl
Apr 30, 2021 05:42AM Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or R
Mar 10, 2021 04:30PM Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
Feb 19, 2021 08:00AM Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020
Feb 1, 2021 07:39AM Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Feb 1, 2021 07:15AM Legend Biotech (LEGN) Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of R/R Multiple Myeloma
Feb 1, 2021 07:15AM Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Dec 21, 2020 07:14AM Legend Biotech (LEGN) Announces Initiation of Rolling Submission of BLA to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for Treatment of R/R Multiple Myeloma
Dec 21, 2020 07:10AM Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory
Dec 21, 2020 07:00AM Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multipl
Dec 15, 2020 04:30PM Legend Biotech to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Dec 14, 2020 04:30PM Legend Biotech Added to the NASDAQ Biotechnology Index
Dec 11, 2020 08:05PM Annual Changes to the Nasdaq Biotechnology Index
Dec 5, 2020 03:12PM Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple
Dec 5, 2020 03:00PM Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Dec 5, 2020 03:00PM Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple
Dec 3, 2020 08:00AM Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors
Nov 24, 2020 08:00AM Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting
Nov 9, 2020 11:07AM Legend Biotech (LEGN) Announces Ye Wang Appointed Chairwoman of the Board, Ying Huang Named CEO
Nov 9, 2020 08:05AM Legend Biotech Announces Leadership Transition
Nov 9, 2020 08:05AM Legend Biotech Announces Leadership Transition
Nov 5, 2020 07:05AM Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory M
Oct 5, 2020 07:03AM Top FDA Official, Amy Abernethy, to Keynote Veeva R&D and Quality Summit Online
Aug 25, 2020 07:00AM BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors
Aug 5, 2020 05:37PM The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Inv
View More Recent Stories